|
Apr 9
|
AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY
|
|
Apr 9
|
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
|
|
Apr 4
|
AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo
|
|
Apr 4
|
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
|
|
Apr 4
|
European Equities Spiral in Friday Trading Amid Global Selloff Sparked by US Tariffs
|
|
Apr 4
|
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
|
|
Apr 4
|
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
|
|
Apr 4
|
AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?
|
|
Apr 3
|
Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs
|
|
Apr 3
|
How Trump's tariffs will impact your finances and the UK economy
|
|
Apr 3
|
Trending tickers: Nvidia, Tesla, Nike, AstraZeneca and Standard Chartered
|
|
Apr 2
|
Q4 2024 AIM ImmunoTech Inc Earnings Call
|
|
Apr 1
|
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
|
|
Apr 1
|
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
|
|
Apr 1
|
Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins
|
|
Apr 1
|
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
|
|
Mar 31
|
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
|
|
Mar 31
|
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
|
|
Mar 31
|
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
|
|
Mar 31
|
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
|